June 13, 2017
DENVER, Colo. (Embargoed until 4:30 P.M. MT, Tuesday, June 13, 2017) – More people die of Alzheimer’s disease than prostate and breast cancer combined. Identifying the disease before major symptoms arise is critical to preserving brain function and helping patients maintain quality of life. A new study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates that a single dual time-point PET scan could identify important biomarkers of Alzheimer’s disease.
The Alzheimer’s Association reports that more than 5 million Americans are estimated to be living with Alzheimer’s disease. This number is expected to swell as high as 16 million by 2050, when Alzheimer’s and other dementias could cost the U.S. more than $1 trillion.
For this study, researchers assessed a procedure called dual time-point fluorine-18 Florbetaben (18F-FBB) PET imaging, which involves the injection of a single radiotracer, 18F-FBB, and two scans performed to observe blood flow and amyloid burden in the brain—two biomarkers for neurodegenerative disease, including Alzheimer’s.
“Until now, researchers conducted two separate molecular imaging procedures to glean information about beta-amyloid buildup and neuronal injury in the brain,” said Henryk Barthel, MD, PhD, from the Department of Nuclear Medicine, University Hospital Leipzig, in Leipzig, Germany. “This study provides proof-of-concept that information about both biomarkers can be obtained from the administration of a single PET tracer.”
The study examined 112 subjects (ages 62-82, with 53 women), 41 diagnosed with mild cognitive impairment, 50 with probable or possible Alzheimer’s and 21 with another dementia. Dual time-point 18F-FBB PET scans were conducted during the first 10 minutes of the procedure and again from the 90-to-110-minute mark. Researchers performed quantitative and visual analyses of PET data. With this data, they were able to determine both neuronal injury and amyloid load in all subjects. At least one biomarker was positive in 39 percent of the subjects with mild cognitive impairment, in 37 percent of patients with possible Alzheimer’s dementia, and in 72 percent of patients with probable Alzheimer’s dementia.
Larger prospective trials are needed to further validate this research, but if these results continue, dual time-point 18F-FBB PET could supplement diagnostic dementia workups by providing essential information about Alzheimer’s pathology in a convenient and clinically useful manner.
Figure: Dual time-point, single PET session 18F-Florbetaben images of two cognitively impaired subjects. While subject #1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer’s disease biomarkers were negative in subject #2 (right). Credit: Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany;
Scientific Paper 556: “Dual time-point 18F florbetaben PET delivers dual biomarker information in mild cognitive impairment and Alzheimer’s dementia,” Lisa Florek, Solveig Tiepolt, Swen Hesse, Thies Jochimsen, Julia Luthardt, Bernhard Sattler, Marianne Patt, Osama Sabri, Henryk Barthel, Dorothee Saur, Karl-Titus Hoffmann, and Joseph Classen, Leipzig University, Leipzig, Germany; Hermann-Josef Gertz, Leipzig University Hospital, Leipzig, Germany; and Matthias L. Schroeter and Arno Villringer, Leipzig University Hospital and Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany, SNMMI’s 64th Annual Meeting, June 10–14, 2017, Denver, Colo.
Please visit the SNMMI Media Center for more information about molecular imaging and personalized medicine. To schedule an interview with the researchers, please contact Laurie Callahan at (703) 652-6773 or email@example.com. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today’s medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.
SNMMI’s more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.